Study on ISM3412 for Patients with Advanced or Metastatic Solid Tumors

Inclusion Criteria

• Adults aged 18 or older.
• Have advanced or metastatic solid tumors that cannot be surgically removed and have a specific genetic deletion (MTAP deletion).
• Have tried standard treatments without success, cannot tolerate them, or have no standard treatment options available.
• Have tumors that can be measured or evaluated.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 12 weeks.
• Have adequate organ function based on medical tests.
• Be able to understand and sign a consent form and follow study requirements.

Exclusion Criteria

• Have previously been treated with MAT2A or PRMT inhibitors.
• Have participated in another clinical trial within the last 28 days.
• Have received any anti-cancer treatment within the last 28 days.
• Have not fully recovered from side effects of previous treatments.
• Have had another type of cancer diagnosed or treated in the last 3 years.
• Have a history of Gilbert's syndrome or myelodysplastic syndrome.
• Have had an organ or stem cell transplant.
• Have active or untreated cancer in the brain or central nervous system.
• Have serious heart or blood vessel diseases.
• Have an uncontrolled infection.
• Have difficulty taking oral medications or have a gastrointestinal condition that affects drug absorption.